Form D · Other Technology
Active Genomes Expressed Diagnostics Corp
Washington, DC · CIK 0001964994
Offering snapshot reported Feb 15, 2023 · SEC filing
- Reported sold
- $250K Offering amount: $1.75M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Dec 29, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 15, 2023 | Initial | $250,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-473512
Source: Form D, filed Feb 15, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rachel Zayas | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
625 H St Ne #821
Washington, DC, 20002
Washington, DC, 20002